ZYME — Zymeworks Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1937653 ·
Last close
$25.84
Market Cap
$1.78B
52W High
$31.97
52W Low
$21.52
ADV30
1,328,437
Next earnings
2026-11-09
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 256,460,000 — 177,634,000 173,700,000 1,176,413,000 100,464,000 918,160,000
Jun 2026 4,590,000 — -42,145,000 -45,019,000 396,964,000 179,413,000 316,595,000
Mar 2026 2,408,000 — -47,149,000 -44,162,000 478,215,000 244,282,000 314,626,000
Dec 2025 2,515,000 — -44,120,000 -41,209,000 346,527,000 41,157,000 78,026,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-111,964,000
Investing CF
$-297,370,000
Financing CF
$444,875,000
CapEx
$-1,419,000
Dividends Paid
—
Buybacks
$-165,571,000
EPS Diluted TTM
$0.52
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,009,530,000
Inventory
—
Receivables
$413,861,000
ST Investments
$0
EBIT TTM
$52,829,000
Pretax Income TTM
$40,124,000
Interest Exp TTM
$15,346,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$265,972,992
EBITDA
$65,140,000
Free Cash Flow
$-195,686,752
Enterprise Value
$1,764,029,312
Total Cash
$100,464,000
Total Debt
$53,128,000
Shares Out
69,030,691
Trailing EPS
$0.53
Book Value
$3.63
ROE
15.0%
ROA
4.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 105,965,000 -92,535,000 -81,130,000 346,527,000 78,026,000 268,501,000 -33,005,000
Dec 2024 76,304,000 -119,817,000 -122,695,000 463,091,000 124,323,000 338,768,000 -110,058,000
Dec 2023 76,012,000 -138,007,000 -118,674,000 580,880,000 116,074,000 464,806,000 -118,324,000
Dec 2022 412,482,000 130,486,000 124,341,000 648,725,000 155,769,000 492,956,000 144,109,000

TTM Snapshot

Revenues TTM
$37,127,000
NetIncome TTM
$-149,992,000
OpCashFlow TTM
—
Assets (Latest)
$396,964,000
Forward EPS
$0.52

Max Pain — expiry 2027-12-17

max pain strike: $30.00 · spot: $26.04 · call oi: 1,615 · put oi: 3,247
Expected Move to 2027-12-17: ±$11.50 (44.16%) — implied range $14.54 – $37.54 · ATM straddle on $25.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
AGIO AGIOS PHARMACEUTICALS, INC. $1.79B $29.89 —
TRAX First Tracks Biotherapeutics, Inc. $1.83B $43.57 —
ETON Eton Pharmaceuticals, Inc. $1.84B $63.65 —
STOK Stoke Therapeutics, Inc. $1.73B $26.41 —
RARE Ultragenyx Pharmaceutical Inc. $1.70B $16.70 —

News headlines (Yahoo Finance, 1h cache)

Zymeworks Announces $200 Million Share Repurchase Authorization
2026-11-16 11:00 · Yahoo
Milestone Payment Lifts Zymeworks Stock Outlook After Profitable Quarter
2026-11-12 23:23 · Yahoo
Zymeworks Inc. (ZYME) Misses Q3 Earnings Estimates
2026-11-09 22:35 · Yahoo
Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
2026-11-09 21:05 · Yahoo
Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal
2026-11-04 04:33 · Yahoo
Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth
2026-10-29 13:00 · Yahoo
Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside
2026-10-27 23:04 · Yahoo
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
2026-10-27 11:00 · Yahoo
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
2026-10-24 06:30 · Yahoo
Zymeworks stock surges on $813M Roche licensing deal
2026-10-23 13:25 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.